395 related articles for article (PubMed ID: 25165112)
21. Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.
Kobayashi T; Koizumi Y; Takeuchi JS; Misawa N; Kimura Y; Morita S; Aihara K; Koyanagi Y; Iwami S; Sato K
J Virol; 2014 May; 88(10):5881-7. PubMed ID: 24623435
[TBL] [Abstract][Full Text] [Related]
22. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya.
Land AM; Ball TB; Luo M; Pilon R; Sandstrom P; Embree JE; Wachihi C; Kimani J; Plummer FA
J Virol; 2008 Aug; 82(16):8172-82. PubMed ID: 18550667
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
[TBL] [Abstract][Full Text] [Related]
24. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.
Wichroski MJ; Robb GB; Rana TM
PLoS Pathog; 2006 May; 2(5):e41. PubMed ID: 16699599
[TBL] [Abstract][Full Text] [Related]
25. Quantifying the antiviral effect of APOBEC3 on HIV-1 infection in humanized mouse model.
Kurusu T; Kim KS; Koizumi Y; Nakaoka S; Ejima K; Misawa N; Koyanagi Y; Sato K; Iwami S
J Theor Biol; 2020 Aug; 498():110295. PubMed ID: 32335137
[TBL] [Abstract][Full Text] [Related]
26. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.
Desimmie BA; Delviks-Frankenberrry KA; Burdick RC; Qi D; Izumi T; Pathak VK
J Mol Biol; 2014 Mar; 426(6):1220-45. PubMed ID: 24189052
[TBL] [Abstract][Full Text] [Related]
27. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
[TBL] [Abstract][Full Text] [Related]
28. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
[TBL] [Abstract][Full Text] [Related]
29. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
Dang Y; Wang X; York IA; Zheng YH
J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
[TBL] [Abstract][Full Text] [Related]
30. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
Albin JS; Harris RS
Expert Rev Mol Med; 2010 Jan; 12():e4. PubMed ID: 20096141
[TBL] [Abstract][Full Text] [Related]
31. Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F.
Albin JS; Anderson JS; Johnson JR; Harjes E; Matsuo H; Krogan NJ; Harris RS
J Mol Biol; 2013 Apr; 425(7):1172-82. PubMed ID: 23318957
[TBL] [Abstract][Full Text] [Related]
32. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
33. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
34. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.
Gillick K; Pollpeter D; Phalora P; Kim EY; Wolinsky SM; Malim MH
J Virol; 2013 Feb; 87(3):1508-17. PubMed ID: 23152537
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
36. APOBEC proteins and intrinsic resistance to HIV-1 infection.
Malim MH
Philos Trans R Soc Lond B Biol Sci; 2009 Mar; 364(1517):675-87. PubMed ID: 19038776
[TBL] [Abstract][Full Text] [Related]
37. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.
Fourati S; Malet I; Binka M; Boukobza S; Wirden M; Sayon S; Simon A; Katlama C; Simon V; Calvez V; Marcelin AG
AIDS; 2010 Sep; 24(15):2313-21. PubMed ID: 20729708
[TBL] [Abstract][Full Text] [Related]
38. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
39. Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity.
Vetter ML; Johnson ME; Antons AK; Unutmaz D; D'Aquila RT
PLoS Pathog; 2009 Feb; 5(2):e1000292. PubMed ID: 19197360
[TBL] [Abstract][Full Text] [Related]
40. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
Chaipan C; Smith JL; Hu WS; Pathak VK
J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
